Neurology · 1996 · 89 citations · 4 references
MedicineNeurologyPharmacologyClinical PharmacologyNeuropharmacologyPharmacodynamicsDopaminergic PharmacologyNeurodegenerative Disease PharmacologyNeurodegenerative Disease PharmacotherapyParkinson DiseaseParkinsonian DisordersCabergoline TreatmentDopamine Receptor AgonistsDouble-blind TrialsParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyParkinson’s Disease TreatmentPlacebo-controlled Efficacy AssessmentSide Effect Profile
Cabergoline is a dopaminergic agonist relatively specific for the D2 receptor and much longer-acting than other dopamine agonists. We conducted a randomized, placebo-controlled, double-blind study of cabergoline in 188 levodopa/carbidopa-treated patients with suboptimally controlled Parkinson's disease (PD). The cabergoline patients had significantly better Activities of Daily Living (p = 0.032) and Motor Examination (p = 0.031) scores at the conclusion of the trial compared with the placebo group. The daily levodopa dose for the cabergoline patients decreased 18% compared with a 3% reduction for the placebo group (p < 0.001). The amount of time in the "on" state increased more in the cabergoline group (p = 0.022). The side-effect was similar to that seen with other dopamine agonists, and cabergoline was generally well tolerated. We conclude that cabergoline is an effective adjunct to levodopa for the treatment of PD.
4
Chronic unilateral optic neuropathy: A magnetic resonance study
David Eidelberg, M. R. Newton, Glyn Johnson et al. · Annals of Neurology · 1988 · 38 citations